Evaluation of the Medicines and Diagnostics Manufacturing Transformation Fund and the Life Sciences Innovative Manufacturing Fund
Findings from the early‑stage evaluation of the Medicines and Diagnostics Manufacturing Transformation Fund and its successor, the Life Sciences Innovative Manufacturing Fund.
Documents
Details
The funds provided capital grants to support life sciences manufacturing projects in the UK, with objectives including strengthening domestic manufacturing capability, supporting economic growth and enhancing health resilience.
The evaluation was commissioned by the Office for Life Sciences and delivered by Ipsos, covering Medicines and Diagnostics Manufacturing Transformation Fund (MDMTF) and Life Sciences Innovative Manufacturing Fund (LSIMF) projects funded through the 2021 and 2022 calls for proposals.
It includes:
- a process evaluation, to assess efficiency and effectiveness of delivery processes
- an early impact evaluation, to assess whether the funds have begun to deliver on objectives
- a value for money evaluation
The findings are intended to inform the ongoing design and delivery of LSIMF2025-30 and to support future decisions on life sciences manufacturing policy.